EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway
文献类型:期刊论文
作者 | Qi, Xueju3; Zhang, Shuna2; Chen, Zekun3; Wang, Lijun5; Zhu, Wenyong1; Yin, Chuanjin3; Fan, Junting6; Wu, Xiaochen3; Wang, Jing4; Guo, Chuanlong3 |
刊名 | CHEMICO-BIOLOGICAL INTERACTIONS |
出版日期 | 2022-01-25 |
卷号 | 352页码:10 |
ISSN号 | 0009-2797 |
关键词 | Human lung cancer eIF4E EGPI-1 Anticancer Angiogenesis |
DOI | 10.1016/j.cbi.2021.109773 |
通讯作者 | Wang, Jing(vicwj@163.com) ; Guo, Chuanlong(guochuanlong@qust.edu.cn) |
英文摘要 | eIF4E plays an important role in regulating tumor growth and angiogenesis, and eIF4E is highly expressed in a variety of lung cancer cell lines. siRNA eIF4E can significantly inhibit the proliferation of lung cancer cells, indicating that inhibition of eIF4E may become a novel anti-tumor target. In the previous study, we synthesized a series of small molecule compounds with the potential to inhibit eIF4E. Among them, the compound EGPI-1 significantly inhibited the proliferation of a variety of lung cancer cells such as A549, NCI-H460, NCI-H1650 and 95D without inhibiting the proliferation of HUVEC cells. Further studies found that EGPI-1 interfered with the eIF4E/eIF4G interaction and inhibited the phosphorylation of eIF4E in NCI-H460 cells. The results of flow cytometry showed that EGPI-1 induced apoptosis and G0/G1 cycle arrest in NCI-H460 cell. Interestingly, we also found that EGPI-1 induced autophagy and DNA damage in NCI-H460 cells. The mechanism results showed that EGPI-1 inhibited the Ras/MNK/ERK/eIF4E signaling pathway. Moreover, EGPI-1 inhibited tube formation of HUVECs, as well as inhibited the neovascularization of CAM, proving the anti-angiogenesis activity of EGPI-1. The NCI-H460 xenograft studies showed that EGPI-1 inhibited tumor growth and angiogenesis in vivo by regulating Ras/MNK/ERK/eIF4E pathway. Our studies proved that eIF4E was a novel target for regulating tumor growth, and the eIF4E/eIF4G interaction inhibitor EGPI-1 was promising to develop into a novel anti-lung cancer drug. |
资助项目 | National Natural Science Foundation of China[51903243] ; Shandong Provincial Natural Science Foundation[ZR2020QH359] ; State Key Laboratory of Microbial Technology Open Projects Fund[NJYT-18-B29] ; Program for Young Talents of Science and Technology in Universities of Inner Mongolia[BTTCRCQD2018001] ; Doctoral Scientific Research Foundation of Inner Mongolia |
WOS研究方向 | Biochemistry & Molecular Biology ; Pharmacology & Pharmacy ; Toxicology |
语种 | 英语 |
出版者 | ELSEVIER IRELAND LTD |
WOS记录号 | WOS:000791244800001 |
源URL | [http://ir.qdio.ac.cn/handle/337002/178957] |
专题 | 海洋研究所_实验海洋生物学重点实验室 |
通讯作者 | Wang, Jing; Guo, Chuanlong |
作者单位 | 1.Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Thorac Surg, Qingdao 266035, Peoples R China 2.Affiliated Hosp Shandong Univ Tradit Chinese Med, Jinan 250011, Peoples R China 3.Qingdao Univ Sci & Technol, Coll Chem Engn, Dept Pharm, Qingdao 266042, Peoples R China 4.Baotou Teachers Coll, Dept Biol Sci & Technol, Baotou 014030, Peoples R China 5.Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao 266071, Peoples R China 6.Nanjing Med Univ, Sch Pharm, Dept Pharmaceut Anal, Nanjing 211166, Peoples R China |
推荐引用方式 GB/T 7714 | Qi, Xueju,Zhang, Shuna,Chen, Zekun,et al. EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway[J]. CHEMICO-BIOLOGICAL INTERACTIONS,2022,352:10. |
APA | Qi, Xueju.,Zhang, Shuna.,Chen, Zekun.,Wang, Lijun.,Zhu, Wenyong.,...&Guo, Chuanlong.(2022).EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway.CHEMICO-BIOLOGICAL INTERACTIONS,352,10. |
MLA | Qi, Xueju,et al."EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway".CHEMICO-BIOLOGICAL INTERACTIONS 352(2022):10. |
入库方式: OAI收割
来源:海洋研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。